Erin Xie

AA
10 Years of experience

Professional background

Joined SSRM, whicn mergered with BlacRcok, in 2001. Research Associate covering the pharma industry, Bernstein.

Educational background

MBA, Massachusetts Institute of Technology Sloan School of Management. PhD in Biochemistry, Unviersity of California. BSc in Chemistry, Beijing University.

Performance

16.09%

Manager Annualised Return Since Inception

13.65%

Benchmark Annualised Return since Inception

Manager Performance

Manager

Benchmark

Dif.

Inception

16.09%
13.65%
2.44%

5Y

13.37%
12.33%
1.04%

Data as at 30 June 2021.

Risk Statement / Disclaimer: Data is collected by Vadevalor. Care has been taken to ensure that the information is accurate, but Vadevalor neither warrants nor guarantees the contents, nor does it accept any responsibility for errors, inaccuracies or omissions herein. Past performance does not necessarily indicate future returns and should not be the sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise. This listing is for informational purposes only. You should not construe any of this material as investment, financial or other advice.

BGF World Healthscience
Value investing using fundamental analysis
Benchmark
BGF World Healthcare
Class
Class D2
ISIN
LU0827889485
AUM
$ 14,078,120,000
Ongoing Charges
1.06%